Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00030303|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : April 28, 2017
RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response to kill cancer cells.
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Biological: recombinant 70-kD heat-shock protein||Phase 1|
- Determine the feasibility of vaccination with autologous heat shock protein 70 in patients with chronic phase chronic myelogenous leukemia.
- Determine the toxicity of this vaccination in these patients.
OUTLINE: Patients undergo leukapheresis to obtain peripheral mononuclear cells (PMNCs). Heat shock protein 70 (HSP70) is derived from the autologous PMNCs. Patients receive HSP70 intradermally once weekly for 8 weeks.
Patients are followed for 2 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Feasibility And Toxicity Study Of Vaccination With HSP70 For The Treatment Of Chronic Myelogenous Leukemia In Chronic Phase|
|Actual Study Start Date :||January 2001|
|Actual Primary Completion Date :||January 2004|
|Actual Study Completion Date :||January 2004|
recombinant 70-kD heat-shock protein
Biological: recombinant 70-kD heat-shock protein
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00030303
|United States, Connecticut|
|University of Connecticut Health Center|
|Farmington, Connecticut, United States, 06030-1601|
|Study Chair:||Zihai Li, MD, PhD||UConn Health|